glp 1 and type 2 diabetes GLP-1 Receptor Agonists: A Game-Changer for Ozempic and GLP-1 agonists- when

Tirzepatide did not increase risks of adverse renal events, urinary tract infections, nephrolithiasis (kidney stones), acute kidney injury, or renal cancer compared to placebo, insulin, or other GLP-1 receptor agonists

Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy

Despite the rapid expansion of GLP-1RAs applications in fields such as endocrinology, cardiology, and neurology, their potential relevance in sepsis remains relatively underrepresented in the literature

Of these, type I hypersensitivity is the most common mechanism of reaction